Conclusion: This systematic review demonstrated that TUDCA has neuroprotective effect on in vivo and in vitro models of retinal disorders, reinforcing the currently available evidence that TUDCA could be a promising therapeutic agent in retinal diseases treatment. However, well designed clinical trials are necessary to appraise the efficacy of TUDCA in clinical setting.
PubMed 37691227 ↗Tudca
The short answer. Most people who report on Tudca say it helped (80% of 32). It is most often used for digestion: 86% of 7 reports say that improved. It is well studied — 4 meta-analyses on PubMed.
From 158 mentions in total — the rest didn't say how it went and aren't counted.
What Tudca does, according to users
Of the people who reported each effect, the share who said it got better.
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 4 meta-analyses on PubMed ↗ · 14 randomized trials ↗
Conclusion: Because no source report documents blinding of outcome assessment, the pooled estimate should be read as an upper bound. In conclusion, TUDCA and 4-PBA act as chemical chaperones that alleviate ER stress and may prevent terminal UPR activation and preserve the beta-cell exocytotic machinery, positioning them as candidate disease-modifying agents that merit confirmatory clinical evaluation.
PubMed 42653271 ↗Conclusion: In addition, findings suggest that all the three bile acids would be equally beneficial in models of Huntington's disease, whereas UDCA and TUDCA would be more beneficial in models of Parkinson's disease and Alzheimer's disease, while GUDCA in models of bilirubin encephalopathy and TUDCA in models of depression. Overall, this review confirms the therapeutic potential of UDCA, GUDCA and TUDCA in neurological, neurodegenerative and neuropsychiatric disorders, proposing bile acids as potential alternative therapeutic approaches for patients suffering from these disorders.
PubMed 34601012 ↗Conclusion: Retinal injury is a significant but under-recognized consequence of severe OAB. Preclinical studies demonstrate that treatments which offer neuroprotective and anti-inflammatory properties mitigate retinal damage in OAB models. However, clinical evidence remains limited. These findings underscore the importance of early retinal evaluation in OAB and highlight the need for future clinical studies to validate and implement effective treatment strategies.
PubMed 42387427 ↗44 human trials on ClinicalTrials.gov test Tudca — 21 completed, 5 recruiting now. See all on ClinicalTrials.gov ↗
- AMX0035 and Progressive Supranuclear Palsy · Progressive Supranuclear Palsy, PSP · 2025
- Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis · Amyloidosis, Amyloid · 2026
- TUDCA as a Therapy for Ulcerative Colitis (UC) · Ulcerative Colitis · 2022
Reports to the FDA
Adverse-event reports about supplements containing it, submitted to the US FDA by consumers and doctors.
6 reports name a product containing Tudca (2021–2026); 1 involved hospitalization or worse. Most often reported:
- Fatigue · 2
- Condition aggravated · 2
- Malaise · 1
- Abdominal pain upper · 1
- Nasal congestion · 1
- Alanine aminotransferase increased · 1
A report doesn't prove the supplement caused the problem — many products contain several ingredients, and these counts can't tell you how often it happens. Source: FDA CAERS ↗ · raw reports (openFDA) ↗.
What government agencies say
Official records from US, Canadian and EU regulators, each linked to its source.
NIH has funded 1 research project with Tudca in the title, $43,647 in total (2011–2011). NIH RePORTER ↗
Dosage people report
As stated by users — not a recommendation. Follow the label or your doctor.
Reported side effects
How often each side effect came up across all reports.
What users say
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“While I do take TUDCA primarily for liver health, anecdotally I've noticed... Slight increase in sense of overall wellbeing.”
“I took NAC, taurine, tudca and methylated B vitamins. All these fed and aggravated my hydrogen sulfide overgrowth.”
“I went 1g a day in a single dose for a month or two and then that's it... Personally that regimen has helped me cure my fatty liver.”
“my bloodwork says otherwise. ... I run tudca too and it works great for me.”
Top discussions (5)
Tudca compared
Other options for digestion
Sources
- User reports: 158 mentions in public discussions, quoted with a link to each discussion (e.g. this thread ↗).
- PubMed (US National Library of Medicine, NIH): meta-analyses ↗ · randomized trials ↗
- ClinicalTrials.gov (NIH): registered trials ↗
- NIH RePORTER ↗
- US Food and Drug Administration: CAERS adverse-event reports ↗
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate